Effect of prolactin on carcinoembryonic antigen-specific cytotoxic T lymphocyte response induced by dendritic cells

Clinical and Experimental Immunology

Volumn 137, Issue 2, 2004, Pages 320-328

  Matera, L ^a   Beltramo, E ^a   Martinuzzi, E ^a   Buttiglieri, S ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b Centro OncoEmatologicoSubalpino   (Italy)

Author keywords

Carcinoembrionic antigen; Dendritic cells; Neuroimmunology; T lymphocytes; Tumour immunity

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CHROMIUM 51; CYTOKINE; GAMMA INTERFERON; HLA A2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; PEPTIDE DERIVATIVE; PROLACTIN; PROLACTIN RECEPTOR; TYROSYLLEUCYLSERYLGLYCYLALANYLASPARAGINYLLEUCYLASPARAGINYLLEUCINE; UNCLASSIFIED DRUG;

ANTIGEN SPECIFICITY; ARTICLE; CANCER CELL CULTURE; CELL CULTURE; CELL LINE; CELL STIMULATION; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; HORMONAL REGULATION; HUMAN; HUMAN CELL; INCUBATION TIME; LEUKEMIA CELL LINE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CARCINOMA; T LYMPHOCYTE;

CARCINOEMBRYONIC ANTIGEN; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; HUMANS; INTERFERON TYPE II; PROLACTIN; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 3543034678     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2004.02533.x     Document Type: Article

References (47)

1. Kooijman R, Hooghe-Peters EL, Hooghe R. Prolactin, growth hormone, and insulin-like growth factor-I in the immune system. Adv Immunol 1996; 63:377-154.
2. Matera L. Action of pituitary and lymphocyte prolactin. Neuroimmunomodulation 1997; 4:171-80.
3. Yu-Lee LY. Signal transduction by prolactin receptors. In: Matera R, Rapaport L, eds. Growth and lactogenic hormones. Neuroimmune biology, Vol. 2. Amsterdam: Elsevier, 2002:111-22.
4. Russell DH, Kibler R, Matrisian L, Larson DF, Poulos B, Magun BE. Prolactin receptors on human T and B lymphocytes: antagonism of prolactin binding by cyclosporine. J Immunol 1985; 134:3027-31.
5. Gagnerault MC, Touraine P, Savino W, Kelly PA, Dardenne M. Expression of prolactin receptors in murine lymphoid cells in normal and autoimmune situations. J Immunol 1993; 150:5673-81.
6. Pellegrini I, Lebrun JJ, Ali S, Kelly PA. Expression of prolactin and its receptor in human lymphoid cells. Mol Endocrinol 1992; 6:1023-31.
7. Whiteside TL, Herberman RB. The role of natural killer cells in immune surveillance of cancer. Curr Opin Immunol 1995; 7:704-10.
8. Trinchieri G. Natural killer cells wear different hats: effector cells of innate resistance and regulatory cells of adaptive immunity and of hematopoiesis. Semin Immunol 1995; 7:83-8.
9. Matera L, Muccioli G, Cesano A, Bellussi G, Genazzani E. Prolactin receptors on large granular lymphocytes: dual regulation by cyclosporin A. Brain Behav Immun 1988; 2:1-10.
10. Matera LG, Bellone J, Lebrun PA et al. Role of prolactin in the in vitro development of interleukin-2-driven anti-tumoral lymphokine-activated killer cells. Immunology 1996; 89:619-26.
11. Cesano A, Oberholtzer E, Contarini M, Geuna M, Bellone G, Matera L. Independent and synergistic effect of interleukin-2 and prolactin on development of T- and NK-derived LAK effectors. Immunopharmacology 1994; 28:67-75.
12. Gaidano G, Contarini M, Pastore C, Saglio G, Matera L. AIDS-related Burkitt's-type lymphomas are a target for lymphokine-activated killers induced by interleukin-2 and prolactin. P Soc Exp Biol Med 1996; 213:196-205.
13. Matera L, Buttiglieri S, Moro F, Geuna M. Effect of prolactin on Natural Killer and MHC-restricted cytotoxic cells. In: Matera R, Rapaport L, eds. Growth and lactogenic hormones. Neuroimmune biology, Vol. 2. Amsterdam: Elsevier, 2002:205-18.
14. Matera L, Galetto A, Geuna M et al. Individual and combined effect of GM-CSF and prolactin on maturation of dendritic cells from blood monocytes under serum-free conditions. Immunology 2000; 108:29-36.
15. Matera L, Mori M, Geuna M, Buttiglieri S, Palestro G. Prolactin in autoimmunity and antitumor defence. J Neuroimmunol 2000; 109:47-55.
16. Banchereau J, Steinman R. Dendritic cells and the control of immunity. Nature 1998; 392:245-52.
17. + T-helper and a T-killer cell. Nature 1998; 393:474-8.
18. Matera L, Cutufia M, Geuna M et al. Prolactin is an autocrine growth factor for the Jurkat human T leukemic cell line. J Neuroimmunol 1997; 79:12-21.
19. Kooijman R, Gerlo S, Coppens A, Hooghe-Peters EL. Myeloid leukemic cells express and secrete bioactive pituitary-sized 23 kDa prolactin. J Neuroimmunol 2000; 110:252-8.
20. Matera L, Geuna M, Pastore C et al. Expression of prolactin and prolactin receptors by non-Hodgkin's lymphoma cells. Int J Cancer 2000; 85:124-30.
21. Ben-Jonathan N, Liby K, Mcfarland M, Zinger M. Prolactin as an autocrine/paracrine growth factor in human cancer. Trends Endocrinol Metab 2002; 13:245-50.
22. Salazar-Onfray F. Interleukin-10: a cytokine used by tumors to escape immunosurveillance. Med Oncol 1999; 16:86-94.
23. Freeman GJ, Sharpe AH, Kuchroo VK. Protect the killer: CTLs need defenses against the tumor. Nat Med 2002; 8:787-9.
24. Salter RD, Howell DN, Cresswell P. Genes regulating HLA class I antigen expression in T B lymphoblast hybrids. Immunogenetics 1985; 21:235-46.
25. Sekiguchi M, Sakakibara K, Fuji G. Establishment of cultured cell lines derived from a human gastric carcinoma. Jpn J Exp Med 1978; 48:61-8.
26. Romani N, Reider D, Heuer M, Ener S, Eibl B, Schuler G. Generation of mature dendritic cells from human blood: an improved method with special regard to clinical applicability. J Immunol Meth 1996; 196:137-51.
27. Buttiglieri S, Galetto A, Forno S, De Andrea M, Matera L. Influence of drug-induced apoptotic death on processing and presentation of tumor antigens by dendritic cells. Int J Cancer 2003; 106:516-20.
28. Muraro R, Wunderlich D, Thor A et al. Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembyonic antigen differentially expressed in human colon carcinomas versus normal human adult tissues. Cancer Res 1985; 45:5769-80.
29. Walter EA, Greenberg PD, Gilbert MJ, Watanabe KS, Thomas ED, Riddell SR. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogenic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333:1038-44.
30. Nukaya I, Yasumoto M, Iwasaki T et al. Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte. Int J Cancer 1999; 80:92-7.
31. Pross HF, Baines MO, Rubin P, Shragge P, Petterson MS. Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cells activity. J Clin Immunol 1981; 1:51-64.
32. + T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens. J Immunol Meth 1997; 203:141-52.
33. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995; 87:982-90.
34. Morse MA, Deng Y, Coleman D et al. A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 1999; 5:1331-8.
35. Matera L, Contarini M, Bellone G, Forno B, Biglino A. Up-modulation of interferon-gamma mediates the enhancement of spontanous cytotoxicity in prolactin-activated natural killer cells. Immunology 1999; 98:386-92.
36. Garner R, Helgason CD, Atkinson EA et al. Characterizazion of a granule-independent lytic mechanism used by CTL hybridomas. J Immunol 1994; 153:5413-21.
37. Kagi D, Vignaux F, Ledermann B et al. Fas and perform pathways as major mechanism of T cell-mediated cytotoxicity. Science 1994; 265:528-30.
38. Yu-Lee L. Stimulation of interferon regulatory factor-1 by prolactin. Lupus 2001; 10:691-9.
39. Dogusan Z, Book ML, Verdood P, Yu-Lee LY, Hooghe-Peters EL. Prolactin activates interferon regulatory factor-1 expression in normal lympho-hemopoietic cells. Eur Cytokine Netw 2000; 11:435-42.
40. Duncan GS, Mattrucker HV, Kagi D, Matsuyama T, Mak TW. The transcription factor interferon regulatory factor-1 is essential for natural killer cell function in vivo. J Exp Med 1996; 184:2043-8.
41. Krumenacker JS, Montgomery DW, Buckley DJ, Gout PW, Buckley AR. Prolactin receptor signaling: shared components with the T-cell antigen receptor in Nb2 lymphoma cells. Endocrine 1998; 9:313-20.
42. Wells JA, de Vos AM. Structure and function of human growth hormon: implication for the hematopoietin. Ann Rev Biophys Biomol Struct 1993; 22:329-51.
43. Hooghe R, Devos S, Dogusan Z, Hooghe-Peters EL. Signal transduction and modulation of gene expression by prolactin in human leukocytes. In: In: Matera R, Rapaport L, eds. Growth and lactogenic hormones. Neuroimmune biology, Vol. 2. Amsterdam: Elsevier, 2002:123-36.
44. Goffin VN, Binart P, Clement-Lacroix B et al. From the molecular biology of prolactin and its receptor to the lessons learned from knockout mice models. Genet Anal 1999; 15:189-201.
45. Bouchard B, Ormandy CJ, Di Santo JP, Kelly PA. Immune system development and function in prolactin receptor-deficient mice. J Immunol 1999; 163:576-82.
46. Dorshkind K, Horseman ND. Anterior pituitary hormones, stress, and immune system homeostasis. Bioessays 2001; 23:288-94.
47. Matera L, Mori M. Cooperation of pituitary hormone prolactin with interleukin-2 and interleukin-12 on production of interferon-gamma by natural killer and T cells. Ann NY Acad Sci 2000; 917:503-13.